Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$555M |
| 2 |
Citigroup
C
|
+$407M |
| 3 |
Medtronic
MDT
|
+$401M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$392M |
| 5 |
Gilead Sciences
GILD
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.43B |
| 2 |
Amazon
AMZN
|
+$1.32B |
| 3 |
Apple
AAPL
|
+$1.1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$995M |
| 5 |
Bank of America
BAC
|
+$726M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.47% |
| 2 | Technology | 3.02% |
| 3 | Healthcare | 2.92% |
| 4 | Consumer Discretionary | 2.17% |
| 5 | Financials | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
GRDIW
13926
DELISTED
GRIID Infrastructure Inc. Warrant
GRDIW
| $542 | ﹤0.01% |
+16,167
| New | +$506 |
2024 Q3
0 quarters
|
|
13927
Jones Lang LaSalle
JLL
$13.9B
| $540 | ﹤0.01% |
+2
| New | +$485 |
2024 Q3
0 quarters
|
|
|
SPRB
13928
PUT
Spruce Biosciences
SPRB
$127M
| $522 | ﹤0.01% |
15
-622
| -98% | -$22.8K |
2024 Q1
2 quarters
|
|
13929
PUT
Aveanna Healthcare
AVAH
$2.71B
| $520 | ﹤0.01% |
100
-1,000
| -91% | -$4.52K |
2024 Q1
2 quarters
|
|
|
MNTSW
13930
DELISTED
Momentus Inc Warrant
MNTSW
| $520 | ﹤0.01% |
52,529
-22,568
| -30% | -$214 |
2024 Q2
1 quarter
|
|
13931
PUT
IGC Pharma
IGC
$28.8M
| $512 | ﹤0.01% |
1,200
+400
| +50% | +$160 |
2024 Q2
1 quarter
|
|
|
FTIIW
13932
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
| $512 | ﹤0.01% |
20,996
+6,065
| +41% | +$158 |
2024 Q2
1 quarter
|
|
|
GENE
13933
DELISTED
Genetic Technologies Ltd.
GENE
| $510 | ﹤0.01% |
+682
| New | +$606 |
2024 Q3
0 quarters
|
|
13934
PUT
Focus Universal
FCUV
$3.11M
| $502 | ﹤0.01% |
+5
| New | +$533 |
2024 Q3
0 quarters
|
|
13935
Vor Biopharma
VOR
$1.09B
| $499 | ﹤0.01% |
36
-4,196
| -99% | -$76.5K |
2021 Q4
11 quarters
|
|
|
LVTX
13936
PUT
DELISTED
LAVA Therapeutics
LVTX
| $498 | ﹤0.01% |
300
-36,300
| -99% | -$66.4K |
2024 Q1
2 quarters
|
|
13937
CALL
Transact Technologies
TACT
$49.2M
| $486 | ﹤0.01% |
+100
| New | +$416 |
2024 Q3
0 quarters
|
|
|
ICAD
13938
PUT
DELISTED
iCAD Inc
ICAD
| $470 | ﹤0.01% |
300
-300
| -50% | -$430 |
2023 Q3
4 quarters
|
|
|
OLPX
13939
CALL
DELISTED
Olaplex Holdings
OLPX
| $470 | ﹤0.01% |
200
-19,200
| -99% | -$38.9K |
2021 Q4
11 quarters
|
|
|
KZR
13940
PUT
DELISTED
Kezar Life Sciences
KZR
| $464 | ﹤0.01% |
60
-10
| -14% | -$60 |
2022 Q1
10 quarters
|
|
13941
BRC Group Holdings
RILY
$195M
| $457 | ﹤0.01% |
+87
| New | +$965 |
2024 Q3
0 quarters
|
|
13942
Biomea Fusion
BMEA
$90.6M
| $455 | ﹤0.01% |
45
-19,425
| -100% | -$126K |
2024 Q1
2 quarters
|
|
13943
Cardio Diagnostics Holdings Inc Warrant
CDIOW
$642K
| $454 | ﹤0.01% |
+11,631
| New | +$438 |
2024 Q3
0 quarters
|
|
13944
Kodiak Sciences
KOD
$5.83B
| $441 | ﹤0.01% |
+169
| New | +$449 |
2024 Q3
0 quarters
|
|
|
MVSTW
13945
DELISTED
Microvast Holdings Warrants
MVSTW
| $438 | ﹤0.01% |
14,595
-500
| -3% | -$11 |
2024 Q2
1 quarter
|
|
13946
Revelation Biosciences Warrant
REVBW
$5.28K
| $423 | ﹤0.01% |
29,400
-16,453
| -36% | -$230 |
2023 Q1
6 quarters
|
|
|
ELEV
13947
CALL
DELISTED
Elevation Oncology
ELEV
| $420 | ﹤0.01% |
700
| – | – |
2024 Q1
2 quarters
|
|
13948
MediWound
MDWD
$174M
| $415 | ﹤0.01% |
23
-13,608
| -100% | -$248K |
2023 Q4
3 quarters
|
|
|
FLZH
13949
CALL
DELISTED
FLASH SPORTS & MEDIA HLDG
FLZH
| $414 | ﹤0.01% |
12
+8
| +200% | +$279 |
2024 Q1
2 quarters
|
|
|
BNIXW
13950
DELISTED
Bannix Acquisition Corp. Warrant
BNIXW
| $402 | ﹤0.01% |
20,106
-306
| -1% | -$5 |
2024 Q2
1 quarter
|
|
Similar funds
Citadel Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Citadel Advisors held 15,731 positions worth $518B, up 4.9% from $494B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Citadel Advisors's Q3 2024 filing shows 1,612 new, 6,434 increased, 5,866 reduced and 1,610 closed positions. Its largest new stake was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M. The largest sale was Invesco QQQ Trust, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 82% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q3 2024 buy was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M.
- Citadel Advisors added most to NVIDIA in Q3 2024, an estimated $555M increase.
- Citadel Advisors's biggest Q3 2024 reduction was Invesco QQQ Trust, cutting an estimated $1.43B.
- Citadel Advisors fully exited Domino's in Q3 2024, selling an estimated $186M.
- Citadel Advisors's ten largest holdings make up 30% of its $518B portfolio in Q3 2024.
- Citadel Advisors opened 1,612 new positions and closed 1,610 in Q3 2024.
- Citadel Advisors's portfolio value rose 4.9% quarter-over-quarter to $518B.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.